StockNow
Calendar
Log in
U.S. Markets

BioNTech (BNTX) announced that the AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone

StockNow breaking-news AI analysis

BioNTech said AHEAD-MERIT missed its first dual primary endpoint, progression-free survival, in the comparison of BNT113 plus pembrolizumab with pembrolizumab alone.

1 stocks
BNTXBioNTech SE American Depositary Share$91.00Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

UnitedHealth Group (UNH) Q3 2026 (USD): Adj. EPS 4.69 (exp. 4.12), Revenue 112.7bln (exp. 111.31bln). Sees FY Adj. EPS "at least" 20.50 (exp. 19.80)

UNHGeopolitics

Iran and the US remain divided over the sequencing of a diplomatic agreement, Al-Akhbar reports via Kan

Fed

Fed's Waller (Voter, Dovish) says the US remains the dominant country in building AI models and AI could contribute to widening GDP per capita